Lobbying

Accendra Health ACH's latest lobbying report covers Q3 2026, at $200K. The four quarters Q4 2025–Q3 2026 total $1.2M. Its first report covers Q4 2022; the issues it reports most are Medicare/Medicaid and Health Issues.

Accendra HealthACH

Accendra Health stock page

Latest quarter
$200K
Q3 2026 · 1 reports
Last 12 months
$1.2M
Last 4 quarters
vs last quarter
−39.4%
Q3 2026 against the quarter before
First report
Q4 2022
The first quarter a report named it

Lobbying by quarter

Accendra Health lobbying by quarter
Accendra Health lobbying by quarter
QuarterAmountReports
Q4 2022$410K2
Q1 2023$280K2
Q2 2023$280K2
Q3 2023$290K2
Q4 2023$400K2
Q1 2024$310K2
Q2 2024$260K2
Q3 2024$260K2
Q4 2024$290K2
Q1 2025$280K2
Q2 2025$280K2
Q3 2025$270K2
Q4 2025$320K2
Q1 2026$360K2
Q2 2026$330K2
Q3 2026$200K1

Policy issues the reports name

  • Medicare and Medicaid31 reports
  • Health issues29 reports
  • Budget and appropriations9 reports
  • Trade6 reports
  • Veterans6 reports
  • Defense6 reports
  • Environment and Superfund4 reports
  • Government issues3 reports
  • Manufacturing2 reports
  • Transportation1 reports

A report that names several issues counts once for each.

Who was lobbied

  • HOUSE OF REPRESENTATIVES31 reports
  • SENATE31 reports
  • Health & Human Services, Dept of (HHS)3 reports
  • Centers For Medicare and Medicaid Services (CMS)2 reports
  • Office of Management & Budget (OMB)1 reports
  • Office of the Vice President of the United States1 reports
  • U.S. Trade Representative (USTR)1 reports
  • White House Office1 reports

Firms it paid

Firm
In-houseAccendra Health$3.6M16 quarters
NVG$1.2M15 quarters

Former officials lobbying for it

No lobbyist with a covered position.

Lobbying reports

Filed by
09/28for Q3In-house$200K
07/20for Q2NVG$80K
07/13for Q2In-house$250K
07/13for Q2In-house$250K
04/20for Q1NVG$80K
04/15for Q1In-house$280K
01/20for Q4 2025NVG$80K
01/19for Q4 2025In-house$240K
25/10/20for Q3 2025NVG$80K
25/10/15for Q3 2025In-house$190K
25/07/20for Q2 2025NVG$80K
25/07/16for Q2 2025In-house$200K
25/04/19for Q1 2025NVG$80K
25/04/16for Q1 2025In-house$200K
25/01/20for Q4 2024NVG$80K
25/01/20for Q4 2024In-house$210K
24/10/21for Q3 2024NVG$80K
24/10/15for Q3 2024In-house$180K
24/07/22for Q2 2024NVG$80K
24/07/22for Q2 2024In-house$180K